The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm

Journal of Internal Medicine

Volumn 261, Issue 4, 2007, Pages 399-407

  Sakthivel, P ^a   Shively, V ^b   Kakoulidou, M ^a   Pearce, W ^b   Lefvert, A K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Abdominal aortic aneurysm; C reactive protein; Matrix metalloproteinases 9; Soluble co stimulatory molecules

Indexed keywords

B7 ANTIGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GELATINASE B;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANALYTICAL PARAMETERS; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ARTICLE; CASE CONTROL STUDY; CELLULAR IMMUNITY; CIRCULATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANK SUM TEST; STATISTICAL ANALYSIS; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 33947507396     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01773.x     Document Type: Article

References (45)

1. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005; 365: 1577-89.
2. Cornuz J, Sidoti Pinto C, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Public Health 2004; 14: 343-9.
3. Satta J, Laurila A, Paakko P et al. Chronic inflammation and elastin degradation in abdominal aortic aneurysm disease: an immunohistochemical and electron microscopic study. Eur J Vasc Endovasc Surg 1998; 15: 313-9.
4. Stella A, Gargiulo M, Pasquinelli G et al. The cellular component in the parietal infiltrate of inflammatory abdominal aortic aneurysms (IAAA). Eur J Vasc Surg 1991; 5: 65-70.
5. Koch AE, Haines GK, Rizzo RJ et al. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 1990; 137: 1199-213.
6. Davis VA, Persidskaia RN, Baca-Regen LM, Fiotti N, Halloran BG, Baxter BT. Cytokine pattern in aneurysmal and occlusive disease of the aorta. J Surg Res 2001; 101: 152-6.
7. Juvonen J, Surcel HM, Satta J, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1997; 17: 2843-7.
8. Jedynak M, Siemiatkowski A, Gacko M, Mroczko B, Borkowski J, Szmitkowski M. [Serum concentration of interleukin-12 (IL-12) in patients undergoing abdominal aortic aneurysm repair-preliminary report]. Pol Arch Med Wewn 2004; 112: 1173-9.
9. Hamano K, Li TS, Takahashi M et al. Enhanced tumor necrosis factor- alpha expression in small sized abdominal aortic aneurysms. World J Surg 2003; 27: 476-80.
10. Walton LJ, Powell JT, Parums DV. Unrestricted usage of immunoglobulin heavy chain genes in B cells infiltrating the wall of atherosclerotic abdominal aortic aneurysms. Atherosclerosis 1997; 135: 65-71.
11. Gregory AK, Yin NX, Capella J, Xia S, Newman KM, Tilson MD. Features of autoimmunity in the abdominal aortic aneurysm. Arch Surg 1996; 131: 85-8.
12. Ocana E, Bohorquez JC, Perez-Requena J, Brieva JA, Rodriguez C. Characterisation of T and B lymphocytes infiltrating abdominal aortic aneurysms. Atherosclerosis 2003; 170: 39-48.
13. Mazur E, Niedzwiadek J, Wolski A, et al. Chlamydia pneumoniae infection in abdominal aortic aneurysm (AAA) patients and its clinical impact. Pol J Pathol 2004; 55: 155-64.
14. Vammen S, Lindholt JS, Andersen PL, Henneberg EW, Ostergaard L. Antibodies against Chlamydia pneumoniae predict the need for elective surgical intervention on small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001; 22: 165-8.
15. Xiong W, Zhao Y, Prall A, Greiner TC, Baxter BT. Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model. J Immunol 2004; 172: 2607-12.
16. Shimizu K, Shichiri M, Libby P, Lee RT, Mitchell RN. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 2004; 114: 300-8.
17. Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. J Immunol 1998; 161: 3919-24.
18. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-65.
19. Hebbar M, Jeannin P, Magistrelli G, et al. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. Clin Exp Immunol 2004; 136: 388-92.
20. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000; 201: 144-53.
21. Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 989-94.
22. Ip WK, Wong CK, Leung TF, Lam CW. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. Int Arch Allergy Immunol 2005; 137: 45-52.
23. Hock BD, Patton WN, Budhia S, Mannari D, Roberts P, McKenzie JL. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia 2002; 16: 865-73.
24. Hock BD, Starling GC, Patton WN et al. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma 2004; 45: 2111-8.
25. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164: 5015-8.
26. Wang XB, Kakoulidou M, Giscombe R et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002; 130: 224-32.
27. Magistrelli G, Jeannin P, Herbault N et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29: 3596-602.
28. Jeannin P, Magistrelli G, Aubry JP, et al. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 2000; 13: 303-12.
29. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-15.
30. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792-5.
31. Yamaguchi N, Hiraoka S, Mukai T, et al. Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production. J Immunol 2004; 172: 1347-54.
32. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res 2001; 61: 153-61.
33. Sturmhoefel K, Lee K, Gray GS, et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res 1999; 59: 4964-72.
34. Chen A, Meyerson HJ, Salvekar A, Tykocinski ML. Nonglycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors. FEBS Lett 1998; 428: 127-34.
35. Shen W, Wang Y, Geng Y, Si L. Bacterially produced human B7-1 protein encompassing its complete extracellular domain maintains its costimulatory activity in vitro. Chin Med J (Engl) 2000; 113: 714-9.
36. Faas SJ, Giannoni MA, Mickle AP, et al. Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1. J Immunol 2000; 164: 6340-8.
37. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-101.
38. Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004; 5: 1134-42.
39. Crowther M, Goodall S, Jones JL, Bell PR, Thompson MM. Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. J Vasc Surg 2000; 32: 575-83.
40. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RW. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000; 11: 1345-52.
41. Lindholt JS, Jorgensen B, Fasting H, Henneberg EW. Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes. J Vasc Surg 2001; 34: 611-5.
42. Norman P, Spencer CA, Lawrence-Brown MM, Jamrozik K. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation 2004; 110: 862-6.
43. Hobbs SD, Claridge MW, Quick CR, Day NE, Bradbury AW, Wilmink AB. LDL cholesterol is associated with small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 26: 618-22.
44. Szekanecz Z, Shah MR, Pearce WH, Koch AE. Intercellular adhesion molecule-1 (ICAM-1) expression and soluble ICAM-1 (sICAM-1) production by cytokine-activated human aortic endothelial cells: a possible role for ICAM-1 and sICAM-1 in atherosclerotic aortic aneurysms. Clin Exp Immunol 1994; 98: 337-43.
45. Montgomery AM, Sabzevari H, Reisfeld RA. Production and regulation of gelatinase B by human T-cells. Biochim Biophys Acta 1993; 1176: 265-8.